Long-term data and sample platform for research on ALS
Collects and stores patient information and samples to support future ALS research.
Plain-language title generated from the registry record
Registry title: Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Key facts
- Where
- Edmonton, Montreal, Québec, and Toronto, CanadaSee the 4 sites
Where in Canada
- University of AlbertaEdmonton, CanadaTaking people
- McGill University / Montreal Neurological Institute and HospitalMontreal, CanadaTaking people
- CHU de Quebec -Universite de LavalQuébec, CanadaTaking people
- University of Toronto / Sunnybrook Health Sciences CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alberta
- Trial code
- NCT05204017
- Record updated
- 13 April 2026
- Original description
CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.Read full original descriptionShow less
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.
Inclusion: Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care); Be of the age of majority in their province of residence/treatment; Have the cognitive capacity to provide informed consent; Have proficiency in English or French in order to understand study instructions and respond to questionnaires; Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled; Be the age of majority in their province of residence/treatment; Have the cognitive capacity to provide informed consent; Have proficiency in English of French to understand study instructions and respond to questionnaires.
Exclusion: A history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy); A history of psychiatric disease (e.g. depression, bipolar disease) that is clinically diagnosed and/or with the current use of psychiatric medications (e.g. antidepressants) for an indication of a psychiatric disease; N/A; [HEALTHY CONTROLS]; Subjects ineligible for an MRI due to a pacemaker or other contraindication according to local MRI policies of the study centre; Significant claustrophobia that would prohibit an MRI (subjects will be required to lie in an MRI scanner for approximately one hour).
[PATIENTS].